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Low fVc/tLc in preserved Ratio 
impaired Spirometry (pRiSm) is 
associated with features of and 
progression to obstructive lung 
disease
Spyridon fortis1,2*, Alejandro comellas2, Victor Kim3, Richard casaburi4, John E. Hokanson5, 
James D. crapo6, Edwin K. Silverman7 & Emily S. Wan7,8
One quarter of individuals with Preserved Ratio Impaired Spirometry (PRISm) will develop airflow 
obstruction, but there are no established methods to identify these individuals. We examined the utility 
of FVC/TLC in identifying features of obstructive lung disease. The ratio of post-bronchodilator FVC 
and tLcct from chest ct (fVc/tLcct) among current and former smokers with pRiSm (feV1/fVc ≥ 0.7 
and FEV1 < 80%) in COPDGene was used to stratify subjects into quartiles: very high, high, low, and 
very low. We examined the associations between FVC/TLCct quartiles and (1) baseline characteristics, 
(2) respiratory exacerbations, (3) progression to COPD at 5 years, and (4) all-cause mortality. Among 
participants with pRiSm at baseline (n = 1,131), the very low FVC/TLCct quartile was associated with 
increased gas trapping and emphysema, and higher rates of progression to COPD at 5 years (36% versus 
17%; p < 0.001) relative to the very high quartile. The very low FVC/TLCct quartile was associated with 
increased total (iRR = 1.65; 95% CI [1.07–2.54]) and severe (IRR = 2.24; 95% CI [1.29–3.89]) respiratory 
exacerbations. Mortality was lower in the very high FVC/TLCct quartile relative to the other quartiles 
combined. Reduced FVC/TLCct ratio in PRISm is associated with increased symptoms, radiographic 
emphysema and gas trapping, exacerbations, and progression to COPD.
Among individuals in the general population with at least 10 pack-years of cigarette smoking who undergo 
spirometry, 12% have a post-bronchodilator FEV1% predicted below 80% with a FEV1/FVC ratio ≥ 0.71. This 
“non-specific” spirometric pattern, commonly referred to as “restrictive”, has been designated as Preserved Ratio 
Impaired Spirometry (PRISm)2–7. Smokers with PRISm have higher cumulative smoking exposure, reduced 
exercise capacity, and increased mortality compared to smokers with normal lung function1,2,7. PRISm is also 
associated with thicker airway walls relative to smokers with normal spirometry2. PRISm individuals share 
features with COPD patients, and a quarter of subjects with PRISm eventually develop COPD1,2. The range of 
post-bronchodilator FEV1% predicted and percent emphysema on CT among PRISm subjects is wide, indicative 
of a heterogeneous population2. Clustering analysis identified a “PRISm-COPD” subgroup with lower FEV1/FVC 
ratio and higher radiologic CT emphysema relative to the rest of PRISm subjects3. This subgroup may represent 
individuals with early or occult obstructive lung disease who do not meet current diagnostic thresholds for air-
flow limitation.
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In PRISm, total lung capacity (TLC) may help distinguish a restrictive from an obstructive ventilatory 
defect, according to the American Thoracic Society-European Respiratory Society (ATS- ERS) 2005 guidelines8. 
However, a true “restrictive disease” is very unlikely in individuals with risk factors for obstruction lung disease, 
no interstitial lung disease and unremarkable body mass index (BMI). In COPDGene, the prevalence of PRISm 
is 12% despite the fact that participants with interstitial lung disease were excluded and body mass index (BMI) 
in PRISm individuals was slightly higher than the BMI in smokers with normal lung function1,2. In addition, a 
single center study showed that among individuals with PRISm and TLC above the lower limit of normal (LLN), 
only 26% had a clinical diagnosis of obstructive lung disease9. Moreover, only 15% of those with PRISm and 
TLC > LLN develop obstructive spirometry over a median follow-up time of 3 years10. Currently, there is no 
available diagnostic test in clinical practice to identify which patients with PRISm may have features classically 
associated with obstructive lung disease.
In obstructive lung diseases, residual volume (RV) may increase at the expense of FVC with total lung capacity 
(TLC) remaining normal11. Conversely, RV may increase with a preserved FVC resulting in an increased TLC. 
Both processes result in reduced FVC/TLC ratio which may antedate the development of obstruction diagnosed 
using standard FEV1/FVC criteria. A disproportionate decrease of FVC relative to TLC may occur in patients with 
a restrictive ventilatory defect that coexists with obstructive lung disease12. Thus, FVC/TLC represents a compos-
ite measure that may be able to identify an occult obstructive ventilatory defect. FVC can be readily obtained from 
spirometry, while TLC, typically assessed by plethysmography, can also be quantified using an inspiratory chest 
CT (TLCCT), with prior studies demonstrating strong correlations with the plethysmography results13,14.
We hypothesized that reduced FVC/TLC ratio in PRISm is associated with clinical, functional and radio-
graphic features of obstructive lung disease, acute respiratory events and increased mortality, and progression 
to COPD. To investigate our hypothesis, we examined current and former smokers with PRISm enrolled in the 
COPDGene study.
Methods
Data collection. We analyzed data from participants in the COPDGene study, an ongoing study conducted 
at multiple clinical centers through the United States (http://www.copdgene.org/). Participants were current and 
former smokers with ≥10 pack-years of smoking who self-identified as non-Hispanic whites (NHW) or African 
Americans (AA) and were between the ages of 45–80 years at enrollment. The institutional review boards at each 
participating center approved the study protocol and written informed consent was obtained from all partici-
pants. Details of the study protocol have been published previously15. Briefly, participants completed a modified 
American Thoracic Society Respiratory Epidemiology questionnaire, St. George’s Respiratory Questionnaire 
(SGRQ), and 6-minute walk test (6-MWT) at the enrollment visit. Dyspnea was assessed using the modified 
Medical Research Council (mMRC) scale. Participants performed pre- and post-bronchodilator spirometry. The 
complete study protocols were performed in accordance with the relevant guidelines and regulations of American 
Thoracic Society–European Respiratory Society (ATS-ERS)16. Volumetric chest CT scans were obtained at TLCCT 
(maximal inspiration) and at functional residual capacity (FRCCT) (end-tidal expiration) using multidetector CT 
scanners15. FRC and TLC% predicted were calculated based on the predicted values17. Percent emphysema and 
gas trapping were quantified using 3D Slicer software (www.airwayinspector.org)15.
We included participants with PRISm at enrollment. We excluded individuals with significant interstitial lung 
disease or bronchiectasis on chest CT, those with missing post-bronchodilator spirometry or TLCCT measure-
ments at baseline, and participants with post-bronchodilator FVC > TLCCT at enrollment. Approximately 5 years 
after the enrollment visit, participants were invited for a follow-up visit that included a repeat spirometry and 
chest CT. Respiratory exacerbation data were collected prospectively after enrollment. Participants were con-
tacted every 6 months after enrollment and completed a standardized questionnaire regarding respiratory exac-
erbations through the Longitudinal Follow Up program. Vital status was also ascertained using information from 
the social security death index and the Longitudinal Follow Up program.
Definitions and outcomes. PRISm was defined as post-bronchodilator FEV1 < 80% predicted and FEV1/
FVC ≥ 0.7. COPD was defined as post-bronchodilator FEV1/FVC < 0.7. The FVC/TLCCT ratio at enrollment was 
calculated using post-bronchodilator FVC (in liters) from spirometry, while TLCCT was measured from volumet-
ric inspiratory chest CT scans.
Co-morbidities and medication usage were self-reported. Percent emphysema was defined by using the per-
centage of lung volume at TLCCT with attenuation less than −950 Hounsfield units (HU)15. Gas trapping was 
quantified as the percentage of lung volume at FRC with attenuation values less than −856 HU15. Parametric 
response mapping analysis was performed on paired registered inspiratory and expiratory images to distinguish 
functional small airways disease (PRMfSAD) from emphysema by Imbio LLC (Minneapolis, MN) using lung den-
sity analysis software18. As previous described19, we defined PRMfSAD as the percentage of lung with evidence of 
gas trapping not due to emphysema (i.e. areas of lung with attenuation < −856 HU on expiration minus area of 
lung with attenuation < −950 HU on inspiration).
Change in FEV1 between enrollment and 5-year follow up visit was calculated using post-bronchodilator 
spirometry. Exacerbations were defined as episodes of worsening respiratory symptoms requiring use of antibiot-
ics and/or systemic steroids. Severe exacerbations were defined as those requiring hospitalizations or emergency 
room visits. Other variable definitions have been previously described15.
Statistical analysis. We stratified PRISm participants at the enrollment visit into quartiles by FVC/TLCCT: 
very high, high, low, and very low. We compared the characteristics of PRISm individuals at the enrollment 
visit, rates of progression to COPD at the 5-year follow-up visit, and exacerbations over the time between the 
FVC/TLCCT quartiles. We used Spearman’s rank correlation to examine changes in continuous variables with 
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increasing FVC/TLCCT. We used the Cochran Armitage trend test to examine proportion changes with increasing 
FVC/TLCCT quartile.
We created multivariable logistic and linear regression models with chronic bronchitis, mMRC and SGRQ 
scores, radiographic measures and 6-MWT distance at the enrollment visit as the dependent variable (outcome) 
and post-bronchodilator FVC/TLCCT quartile at the enrollment as the independent variable (predictor). All mod-
els included the following covariates: age and current smoking status at enrollment, gender, race, pack-years 
smoked, body mass index (BMI), history of asthma and congestive heart failure. There were no missing values 
in any of the covariates. We also performed a multivariable linear and logistic regression analysis with change 
in FEV1, 6-MWT distance, radiographic measurements, and progression to COPD at the follow-up visit as the 
dependent variable (outcome) and post-bronchodilator FVC/TLCCT quartile at enrollment as the independent 
variable (predictor). We included the following covariates in these models: age and current smoking status at 
enrollment, gender, race, pack-years smoked, body mass index (BMI), history of asthma and congestive heart 
failure, and change of BMI between enrollment and follow-up visit.
For the exacerbation analysis, we created zero-inflated negative binomial models which included adjustment 
for age and current smoking status at enrollment, gender, race, pack-years smoked, BMI, chronic bronchitis, his-
tory of asthma and congestive heart failure. There were no missing values in any of the covariates. Follow-up time 
was included as an offset in the models as previously described20.
We used Cox proportional hazard regression models to examine the association between post-bronchodilator 
FVC/TLCCT quartile with all-cause mortality. Models included the following covariates: age, gender, race, smok-
ing status, smoking pack-years, BMI, diabetes, history of asthma and congestive heart failure. There were no 
missing values in any of the covariates.
In sensitivity analyses, we repeated selected analyses using PRISm defined as post-bronchodilator 
FEV1 < LLN with a post-bronchodilator FEV1/FVC ≥ LLN and COPD defined as post-bronchodilator FEV1/
FVC < LLN using the NHANES III reference values21. All statistical analyses were conducted using R statisti-
cal software (http://www.r-project.org/) using the following R software packages: ‘dunn.test’, ‘FSA’, ‘pscl’, ‘MASS’, 
‘AER’, ‘survival’, and ‘DescTools’.
Ethics approval. The institutional review boards at each participating center approved the study protocol. 
Details of the study protocol have been published previously16.
Results
Of 10,199 COPDGene participants with at least 10 or more pack-years of smoking and no significant intersti-
tial lung disease or bronchiectasis, 1,260 of them had PRISm at the enrollment visit. After excluding one indi-
vidual with no available post-bronchodilator spirometry, 121 with no TLCCT measures and 7 individuals with 
FVC > TLCCT, 1,131 participants were included in the analysis. The median value of FVC/TLCCT was 0.59 
(IQR = 0.53–0.66). Of these 1,131 participants, 617 of them had acceptable spirometry measurements at the 5-year 
follow-up visit, 967 had available data regarding respiratory exacerbations, and 960 had vital status data available.
Baseline characteristics at the enrollment visit (n = 1,131). Table 1 shows the characteristics of 
participants by FVC/TLCCT quartile. Age, BMI, pack-years smoking exposure, mMRC and SGRC scores, % 
emphysema and gas trapping, and % functional small airways disease increase with decreasing FVC/TLCCT. An 
increased proportion of females and decreased proportion of African Americans were associated with decreasing 
FVC/TLCCT. Participants in the lower FVC/TLCCT quartiles a higher prevalence of comorbidities.
In multivariable-adjusted analyses, the very low FVC/TLCCT quartile was associated with an average of 3.31% 
higher radiographic gas trapping (95% CI = 1.85–4.76; p < 0.001), and 3.26% higher PRMfSAD (95% CI = 1.40–
5.12; p < 0.001) relative to the very high quartile (Fig. 1). Lower quartiles were also associated with higher % 
emphysema. The very low quartile was associated with a trend towards higher SGRQ (3.63; 95% CI = −0.17 to 
7.44; p = 0.06) (Supplementary Table S1).
Progression to COPD at 5-year follow-up. Among participants with valid spirometry at the 5-year fol-
low up visit (n = 617), approximately 35.9% (56 of 156) of individuals in very low FVC/TLCCT quartile pro-
gressed to COPD, while 23% (37 of 160), 22% (35 of 156), and 17% (25 of 145) of individuals in the low, high, 
and very high FVC/TLCCT quartiles, respectively, progressed to COPD (Fig. 2; Cochran-Armitage test for trend 
p < 0.001). In the multivariable-adjusted analysis, the very low FVC/TLCCT quartile at enrollment was associated 
with progression to COPD with an OR of 2.67 (95% CI = 1.45–5.00; p < 0.001) relative to the highest quartile 
(Supplementary Table S2).
Longitudinal changes in spirometry, functional capacity, and radiographic fea-
tures. Supplement Table S2 shows changes in spirometry, functional capacity, and radiographic features 
between enrollment and follow-up visit. In the adjusted analysis, the very low FVC/TLCCT quartile at enrollment 
was associated with increase of 2.74% radiographic gas trapping (95% CI = 0.55–4.93; p = 0.014) relative to the 
highest quartile (Supplementary Table S3). FVC/TLCCT was not associated with change in FEV1, 6-MWT dis-
tance or % emphysema over time. There were no differences in the rate of decline in FEV1 by current smoking 
status at enrollment (combined and by FVC/TLC quartile - data not shown).
Respiratory exacerbations. Of 967 subjects with exacerbation data available, 349 (36.1%) reported at least 
one exacerbation and 196 (20.3%) reported at least one severe exacerbation during a median follow-up time of 
6.4 years (IQR = 3.8 to 7.4). Approximately, 44% (115 of 262), 37% (93 of 250), 31% (72 of 232), and 31% (69 
of 223) in the very low, low, high, and very high Quartiles had at least one exacerbation during the time period 
(Cochran-Armitage trend test p < 0.001). In the very low, low, high, and very high Quartiles, 26% (67 of 262), 
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18% (46 of 250), 16% (38 of 232), and 20% (45 of 223) of participants, respectively, had at least one severe res-
piratory exacerbation, with a trend towards significance (Cochran-Armitage p = 0.095). We created multivari-
able zero-inflated negative binomial models to examine the association of FVC/TLCCT quartile with respiratory 
exacerbations (Fig. 3). The very low FVC/TLCCT quartile was associated with increased relative risk for total 
exacerbations (IRR = 1.65; 95% CI = 1.07–2.54; p = 0.023) and severe (IRR = 2.24; 95% CI = 1.29–3.89; p = 0.004) 
exacerbations relative to the “very high” FVC/TLC quartile (Supplementary Table S4).
Mortality (n = 960). During a median follow-up time of 2,408 days (IQR = 2158 to 2622), 12.9% (32 of 
248) subjects died in the Very Low quartile, 11% (27 of 246) died in the low quartile, 11.3% (28 of 247) died in 
the High quartile, and 5.9% (13 of 219) died in the very high quartile (Cochran-Armitage trend test p = 0.02). A 
Kaplan-Meier plot of mortality by FVC/TLCCT quartile at enrollment is shown in Fig. 4.
In Cox proportional hazards models adjusted for age at enrollment, sex, race, BMI, current smoking at enroll-
ment, cumulative smoking exposure, diabetes, history of asthma and congestive heart failure, increased mortality 
in the high quartile with a trends towards an increased mortality in the low and very low quartiles relative to the 
very high quartile was observed (Table 2). In a Cox proportional hazards model examining individuals in the 
very high quartile relative to all other quartiles (high, low, very low) combined, a reduced risk of mortality was 
observed (HR = 0.53, 95% CI = 0.28–0.97,p = 0.040).
FVC/TLC Quartile
High air trapping → Low air trapping
P for 
trend
Very Low 
quartile (n = 283)
Low quartile 
(n = 283)
High quartile 
(n = 282)
Very High 
quartile (n = 283)
FVC/TLCCT <0.53 0.53–0.59 0.59–0.66 >0.66
Age, y ± SD 62.83 ± 8.82 57.68 ± 7.34 55.70 ± 6.96) 52.84 ± 6.27 <0.001
Female, n (%) 186 (65.7%) 169 (59.7%) 143 (50.7%) 115 (40.6%) <0.001
African American, n (%) 86 (30.4%) 89 (31.4%) 126 (44.7%) 174 (61.5%) <0.001
BMI, Kg/m2 ± SD 32.99 ± 7.42 32.84 ± 7.50 30.24 ± 6.88 31.05 ± 6.97 <0.001
Pack-Years ± SD 49.46 ± 28.69 43.51 ± 22.51 39.12 ± 20.08 38.06 ± 22.63 <0.001
Active Smoker, n (%) 154 (54.4%) 162 (57.2%) 180 (63.8%) 213 (75.3%) <0.001
Chronic Bronchitis, n (%) 53 (18.7%) 54 (19.1%) 52 (18.4%) 42 (14.8%) 0.23
mMRC ± SD 1.70 ± 1.47 1.56 ± 1.44 1.21 ± 1.37 1.44 ± 1.50 <0.001
SGRQ ± SD 32.91 ± 22.69 30.06 ± 23.29 24.50 ± 20.54 29.71 ± 23.78 <0.001
Asthma, n (%) 75 (26.5%) 64 (22.6%) 51 (18.1%) 60 (21.2%) 0.064
CHF, n (%) 21 (7.4%) 17 (6.0%) 5 (1.8%) 8 (2.8%) 0.001
DM, n (%) 75 (26.5%) 75 (26.5%) 44 (15.6%) 42 (14.8%) <0.001
HTN, n (%) 150 (53.0%) 151 (53.4%) 133 (47.2%) 120 (42.4%) 0.004
CAD, n (%) 25 (8.8%) 32 (11.3%) 12 (4.3%) 10 (3.5%) <0.001
OSA, n (%) 68 (24.0%) 61 (21.6%) 56 (19.9%) 38 (13.4%) 0.002
CVA, n (%) 15 (5.3%) 10 (3.5%) 7 (2.5%) 7 (2.5%) 0.049
LAMA, n (%) 33 (12.1%) 18 (6.5%) 18 (6.5%) 15 (5.4%) 0.005
ICS, n (%) 19 (7.0%) 19 (6.8%) 12 (4.4%) 13 (4.6%) 0.131
LABA, n (%) 7 (2.6%) 1 (0.4%) 1 (0.4%) 4 (1.4%) 0.2482
ICS/LABA, n (%) 59 (21.6%) 36 (12.9%) 22 (7.9%) 24 (8.6%) <0.001
Post-FEV1% ± SD 65.74 ± 9.65 71.33 ± 7.32 72.04 ± 6.54 73.02 ± 5.92 <0.001
Post-FVC% ± SD 66.70 ± 10.07 72.47 ± 7.68 73.47 ± 7.58 75.05 ± 7.25 <0.001
BDR, n (%) 40 (14.4%) 41 (14.6%) 30 (10.8%) 47 (16.8%) 0.71
§% Emphysema ± SD 2.02 ± 3.32 1.66 ± 2.92 1.48 ± 2.00 1.07 ± 1.53 <0.001
§% Gas trapping ± SD 12.48 ± 8.64 9.06 ± 7.48 8.19 ± 6.65 7.50 ± 5.82 <0.001
‡PRMfSAD, % ± SD 14.63 ± 9.87 10.60 ± 8.65 10.37 ± 9.24 10.13 ± 8.65 <0.001
§FRCCT% ± SD 97.25 ± 18.17 87.62 ± 14.63 80.89 ± 13.00 75.25 ± 12.36 <0.001
TLCCT % ± SD 90.20 ± 13.58 85.82 ± 9.80 77.77 ± 9.48 68.96 ± 9.02 <0.001
#6-MWT, meters ± SD 366.33 ± 110.24 394.00 ± 104.72 406.56 ± 114.12 396.23 ± 109.78 <0.001
Table 1. Baseline characteristics of smokers with preserved ratio impaired spirometry across post-
bronchodilator forced vital capacity/total lung capacity ratio (FVC/TLCCT) quartiles (n = 1,131). §For % GT 
and FRCCT% analysis, data were available for 936 subjects. ‡For PRM data analysis, data were available for 932 
subjects. #For 6-MWT data analysis, data were available for 1,121 subjects. BDR = bronchodilator response; 
BMI = body mass index; CAD = coronary artery disease; CHF = congestive heart failure; DM = diabetes 
mellitus; FRCCT% = functional residual capacity % predicted; HTN = hypertension; ICS = inhaled 
glucocorticosteroids, LABA = long-acting beta-agonist, LAMA = long-acting muscarinic antagonist, mMRC 
= modified Medical Research Council dyspnea score; OSA = obstructive sleep apnea; post-FEV1% = post-
bronchodilator FEV1% predicted; post-FVC% = post-bronchodilator FVC% predicted; PRMfSAD = parametric 
response mapping functional small airways disease; SD = standard deviation; SGRQ = St. George’s Respiratory 
Questionnaire score; TLCCT% = total lung capacity % predicted and 6-MWD = 6-min walk test.
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Sensitivity analysis. When PRISm was defined using LLN criteria, we observed similar findings with those 
in main analysis except that FVC/TLCCT was significantly associated with chronic bronchitis, increased mMRC 
and SGRQ and the association with mortality was attenuated (Supplementary Tables S5–S9 and Fig. S1).
Figure 1. Associations between post-bronchodilator forced vital capacity/total lung capacity (FVC/TLCCT) 
quartiles at enrollment with dyspnea and health-related quality of life scores, chest CT % emphysema and % 
gas trapping, functional small airway disease, and 6-min walk test distance at baseline among smokers with 
Preserved Ratio Impaired Spirometry (PRISm; n = 1,131). Each panel in the figure represents a separate linear 
regression model with categorical post-bronchodilator FVC/TLCCT quartile as the main independent variable 
(exposure) with the “very high” quartile used as the reference category. The dependent variable (outcome) in 
each model was (A) modified Medical Research Council (mMRC) dyspnea score, (B) St. George’s Respiratory 
Questionnaire total score (SGRQ), (C) 6-minute walk test distance (6-MWT in meters), (D) % Emphysema, (E) 
% Gas trapping, and (F) functional small airways disease (PRMfSAD). All models were adjusted for the following 
co-variates: age, sex, race, smoking status, smoking pack-years, body mass index (BMI), history of asthma and 
congestive heart failure, and diabetes mellitus. FVC/TLCCT quartile is plotted on the x-axis while the regression 
coefficient (and 95% CI) for each category is plotted on the y-axis. *For % GT analysis, n = 936 subjects. †For 
PRMfsad data analysis, n = 932 subjects. #For 6-min walk test distance analysis, n = 1,121 subjects.
Figure 2. Progression to COPD (FEV1/FVC < 0.7) at the 5-year follow-up visit by post-bronchodilator forced 
vital capacity/total lung capacity ratio (FVC/TLCCT) quartiles at enrollment in smokers with preserved ratio 
impaired spirometry (n = 617). Cochran Armitage Trend test p < 0.001. Pairwise comparisons between 
quartiles performed using Chi-squared test. *p = 0.026 vs Very High FVC/TLCCT Quartile.
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Discussion
Our study explores the utility of FVC/TLCCT ratio in former and current smokers with PRISm as a potential tool 
to identify individuals with features of and possible increased risk for progression to obstructive lung disease. In 
our cohort, very low FVC/TLCCT was associated with radiographic findings traditionally associated with COPD 
as well as progression to COPD and respiratory exacerbations while very high FVC/TLCCT was associated with 
reduced mortality.
PRISm is a common spirometric pattern with a prevalence between 5% and 20%22–25. Although often referred 
to as a “restrictive spirometric pattern”, 30–40% of patients with PRISm do not have reduced TLC26,27. On average, 
individuals PRISm have higher BMI, but obesity alone does not decrease vital capacity or TLC below the LLN 
in most individuals28. Notably, only about 5% of patients undergoing bariatric surgery for extreme obesity have 
PRISm at preoperative assessment29.
PRISm is comprised of a heterogeneous population with a wide range of BMI, degree of lung function impair-
ment, and radiographic emphysema likely due to different underlying pathological processes in each individual2. 
Subgroups within PRISm may have increased risk for FEV1 decline, progression to COPD, exacerbations, and 
Figure 3. Associations between post-bronchodilator forced vital capacity/total lung capacity (FVC/TLCCT) 
quartiles at enrollment with prospective exacerbations and severe exacerbations in smokers with Preserved 
Ratio Impaired Spirometry (PRISm; n = 967). For exacerbation analysis, data for 967 subjects with PRISm at 
enrollment were available. Zero-inflated negative binomial regression models with post-bronchodilator FVC/
TLCCT as independent variable (exposure) and total exacerbations and severe exacerbations as the dependent 
variables (outcome) were performed. All regression models included the following co-variates: age, sex, race, 
body mass index, smoking status at the enrollment, smoking pack-years, history of asthma and congestive heart 
failure, and chronic bronchitis in the count negative binomial regression and an intercept-only model in the 
zero component. Follow-up time was included as an offset in the models. FVC/TLCCT quartile is plotted on the 
x-axis while the IRR (and 95% CI) for each category is plotted on the y-axis. IRR = incidence rate ratio, FVC/
TLCCT = forced vital capacity/total lung capacity.
Figure 4. Kaplan-Meier Plot of overall survival by forced vital capacity/total lung capacity ratio (FVC/TLCCT) 
quartiles at enrollment in smokers with Preserved Ratio Impaired Spirometry (PRISm, n = 960). Chi-squared 
p-value for differences in mortality by quartile = 0.07.
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mortality. In this manuscript, we utilize FVC/TLC, which decreases in obstructive lung disease11, as a conceptual 
surrogate for RV (which was not directly measured in our cohort) to identify individuals with features obstructive 
lung disease within PRISm. Our finding that individuals with PRISm with low FVC/TLC have increased radio-
graphic emphysema and gas trapping complements work from the SPIROMICS cohort, where that RV/TLC was 
shown to be associated with increased radiographic emphysema and gas trapping in smokers with normal lung 
function30. Apart from the fact that RV/TLC was not available in our cohort, we used FVC/TLC as it may be more 
sensitive to identify the presence of small airway disease than RV/TLC because FVC, a dynamic measure obtained 
at forced expiration, will capture dynamic collapse and air trapping not present during slow exhalation maneu-
ver31,32. Future studies should examine the role of RV/TLC in PRISm. In addition, we did not examine FRC/TLC 
as FRC can be reduced remarkably in obesity28 which may render difficult to interpret those measures when an 
obstructive lung diseases coexists.
Our findings suggest that low FVC/TLCCT may be a possible a marker of early obstructive pulmonary disease. 
Nevertheless, participants in the very low FVC/TLCCT quartile have higher BMI; this contrasts with the common 
knowledge that patients with established obstructive pulmonary disease have often lower BMI. Previous studies 
have shown an inverse relationship of BMI with mortality in COPD, known also as the “obesity paradox” with 
confounders such as exercise capacity and muscle mass possibly contributing towards favorable outcomes33,34. 
In addition, despite the fact that obesity does not typically reduce the FVC below the LLN in subjects without 
lung disease29, higher BMI decreases FVC and increases the FEV1/FVC ratio which can lead to underdiagnosis 
of obstructive pulmonary disease31,35. In COPD subjects with established airflow obstruction, increasing BMI is 
associated with higher FEV1/FVC35.
We acknowledge that the fixed threshold FEV1/FVC < 0.7 diagnostic criterion for COPD endorsed by Global 
Initiative for Chronic Obstructive Lung Disease(GOLD) may have also misclassified individuals with obstructive 
lung disease as PRISm. In a recent large population-based sample (n = 24,207), Bhatt and colleagues showed that 
the discriminative accuracy of FEV1/FVC < 0.7 to predict COPD-related death and/or hospitalization was not 
inferior to FEV1/FVC < LLN36. We assert that because the majority of our findings remained robust on sensitivity 
analyses using LLN-defined lung function categories. FVC/TLC ratio can be utilized to identify individuals with 
features of obstructive lung disease regardless of whether fixed-threshold or LLN criteria are used.
In COPDGene, 40.5% of PRISm individuals and 32.5% of smokers with normal lung function are African 
American2. Differences in the reliability of prediction equations may lead to the “overdiagnosis” of African 
American with PRISm in the absence of true pathology; this may contribute to the lower rates of African 
Americans in the low FVC/TLCCT quartiles. It is also unclear why females were relatively over-represented in the 
lower FVC/TLCCT quartiles. Whether PRISm represents a gender-specific pathway to COPD, or whether tradi-
tional FEV1/FVC criteria systematically misclassify women with COPD is not known37,38. Our sensitivity analysis 
using gender and race specific spirometric criteria to define PRISm showed similar findings. Future studies, espe-
cially in cohorts of diverse ancestry and ethnicity, are warranted to further explore these findings.
Previous studies have shown that air trapping is associated with FEV1 decline. In current and former smokers 
with at least 20 pack-years smoking and normal lung function, RV/TLC is associated with FEV1 decline30. We 
have extended these finding by showing that air trapping (low FVC/TLC) in individuals with PRISm is associ-
ated with progression to COPD. General population studies have also shown that individuals with abnormal 
non-obstructed lung function are at risk for developing COPD39,40. It may seem counterintuitive that low FVC/
TLCCT in PRISm was associated with progression to COPD and respiratory exacerbations, but was not associated 
with FEV1 decline, increase in emphysema, and change in 6-MWT distance over time41. Within COPDGene, 
individuals with PRISm are at increased risk for respiratory exacerbations relative to smokers with normal lung 
function42. However, respiratory exacerbations in PRISm do not result in significant excess lung function decline 
in FEV1 as observed in individuals with established airflow limitation43. A survivor bias may also be present in 
FEV1 decline analysis43. Participants that had poor lung function and low FVC/TLC may have died before the 
follow-up visit. Similarly, we may have not observed changes in 6-MWT distance likely due to the high variability 
of the test44,45.
Population-based studies have shown that PRISm is associated with increased cardiac7 and all-cause mor-
tality1,22. While the increased average BMI in PRISm as a whole may mediate some of the risk associated with 
increased mortality, the association between very high FVC/TLCCT and lower mortality relative to all other quar-
tiles despite concurrent adjustment for BMI, congestive heart failure, and diabetes status in our study suggests 
Quartile
FVC/TLCCT
HR 2.5% 9.75% P value
Very High ref ref ref ref
High 2.12 1.09 4.13 0.028
Low 1.68 0.84 3.36 0.14
Very Low 1.87 0.89 3.87 0.10
Table 2. Associations of post-bronchodilator forced vital capacity/total lung capacity (FVC/TLCCT) quartiles at 
enrollment with mortality in smokers with Preserved Ratio Impaired Spirometry (PRISm; n = 960). Cox Hazard 
regression models with post-bronchodilator FVC/TLCCT quartiles as independent variables (exposure) and 
mortality as the dependent variable(outcome) were performed. All models for mortality included the following 
co-variates: age, sex, race, smoking status, smoking pack-years, body mass index (BMI), history of asthma and 
congestive heart failure, and diabetes mellitus. HR = Hazard Ratio.
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our composite measure may have utility in the risk-stratification of individuals with PRISm. Previous studies in 
COPD have shown associations between RV and mortality46. In Veterans with a history of smoking and normal 
lung function, Zeng et al. showed that RV/TLC is associated with increased respiratory medication use, hospital-
izations, and all-cause mortality47.
Our study is the first one showing that a composite measure of lung function may help to identify patients with 
PRISm who eventually progress to classic airflow obstruction and are at increased risk for respiratory exacerba-
tions and death. The strengths of our study include large sample size, highly granular epidemiological data, axial 
radiographic imaging data, and longitudinal data on clinically relevant outcomes. Despite this, we acknowledge 
the following limitations. RV was not available in our cohort. TLCCT was measured in supine position by chest 
CT, which is usually lower than TLC measured in seated position by plethysmography13. Another limitation is 
possible self-selection bias of subjects who returned for a follow-up visit. Since our cohort includes only smokers, 
our findings cannot be generalized to non-smoking populations and future studies in independent cohorts are 
warranted. In conclusion, FVC/TLCCT can help to identify individuals with PRISm at increased risk for clinical 
events and progression to COPD, and who would benefit from smoking cessation and may be a potential target 
population for treatment trials in the future.
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